14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CGON vs ZLAB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, CG Oncology, Inc. (CGON) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). CGON carries a Unified Composite Score of 45.0/100 (HOLD) at $84.94 (N/M Forward P/E, -4293.5% operating margin), whereas ZLAB carries 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin).
Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. CGON 45.0/100 HOLD), CGON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-4293.5% vs. -63.0% operating margin) and revenue trajectory (-3.7% vs. -6.8% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CGON vs ZLAB. Trailing 12-month operating profitability (CGON -4293.5% vs ZLAB -63.0%) and valuation multiples (CGON N/M vs ZLAB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.0B market capitalization and -63.0% operating margin.
OpEx & R&D Reinvestment63.6% of Rev ($281M)
90D Engineering Disclosures0 Published
Investor FAQ CGON vs ZLAB Key Questions & Quantitative Answers
As of Nov 16, 2026, CG Oncology, Inc. (CGON) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). CGON carries a Unified Composite Score of 45.0/100 (HOLD) at $84.94 (N/M Forward P/E, -4293.5% operating margin), whereas ZLAB carries 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin). Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. CGON 45.0/100 HOLD), CGON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-4293.5% vs. -63.0% operating margin) and revenue trajectory (-3.7% vs. -6.8% YoY).
CGON leads the Growth & Scale pillar: CGON posts -3.7% YoY revenue growth and +0.0% YoY earnings growth on $6.2M TTM revenue (N/A gross margin, -4293.5% operating margin), compared with ZLAB at -6.8% YoY revenue growth and +0.0% YoY earnings growth on $442M TTM revenue (0.6% gross margin, -63.0% operating margin). On trailing 12-month operating scale, CGON generates $6.2M in USD-normalized revenue versus $442M for ZLAB. In operating R&D and SG&A reinvestment, CGON deploys N/A (0 90-day corporate R&D disclosures) versus 63.6% of Rev ($281M) (0 disclosures) for ZLAB.
ZLAB screens cheaper on headline valuation multiples. CGON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ZLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-59.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGON (-28.3% ROE) versus ZLAB (-30.0% ROE) capital efficiency.
In options market volatility and institutional positioning, CGON carries 238.6% implied volatility (85th %ile, Extreme (>80th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.77β · 86% Vol realized risk). By comparison, ZLAB carries 58.4% implied volatility (58th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.